FIG 3.

DENV neutralization by LATV-derived MAbs. A flow-based DENV neutralization assay was used to determine the neutralization potential of the isolated MAbs. (A) Each MAb-containing transfection supernatant (with 1 μg and 0.1 μg of the MAb) was initially screened for neutralization against the four DENV serotypes. The neutralization activity of supernatants was then validated in a follow-up assay, using purified MAbs. Values represent the percent reduction of DENV infectivity (>50%). (B) Summary of the DENV serotype neutralization pattern of the 21 MAbs studied. (C) Representative virus neutralization curves of three isolated nAbs. The neutralization potencies (Neut₅₀) of the selected MAbs were determined by assaying Vero cell infectivity in the presence of serial dilutions of purified MAbs. (D) The neutralization of DENV serotypes by P1C05, P3D05, P4G10 nAbs was validated by the focus reduction neutralization test (FRNT). The purified P3D05 MAb selectively neutralized DENV3. A control anti-SIV antibody was used as a negative control.